Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer PatientsMarius Ilié 1,2,3, Mélanie Ngo-Mai 1, Elodie Long-Mira 1,2, Sandra Lassalle 1,2, Catherine Butori 1, Coraline Bence 1, Marame Hamila 1, Véronique Hofman 1,2,3, Paul Hofman 1,2,3
1Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Hospital University Federation OncoAge, Université Côte d’Azur, 2Institute for Research on Cancer and Aging in Nice (Inserm U1081 and CNRS 7284), Université Côte d’Azur, 3Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, Université Côte d’Azur
To expand the ability of laboratories worldwide to assess the eligibility of patients with lung cancer for treatment with pembrolizumab, in a reliable and reproducible manner, we developed an assay that uses the 22C3 antibody concentrate on a widely available immunohistochemical autostainer, for both biopsy and cytology specimens.
